Hydrocortisone vs placebo
- Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… 2024 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 136 participantsVery low
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Hydrocortisone showed no clear difference in dropouts due to adverse events at 3 months compared with placebo (low certainty).
It is very uncertain whether hydrocortisone changes PTSD rate at 3 months compared with placebo (very low certainty).
The review found no eligible studies for this question.
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher proportion with zero bleeds compared with on‐demand therapy (moderate certainty).
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
Summary of findings table ‐ Concizumab prophylaxis may leads to higher proportion with zero bleeds compared with on‐demand therapy (low certainty).
Summary of findings table ‐ Concizumab prophylaxis showed no clear difference in adverse events ‐ All adverse events compared with on‐demand therapy (low certainty).
Summary of findings table ‐ Concizumab prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (low certainty).